---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000062"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-08-04T20:05:24+00:00"
generated_at: "2026-08-04T20:08:14.203101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere Q2: FILSPARI sales +96% to $141M; FSGS launch drives 2,012 PSFs; net loss $34.8M

## Summary
- U.S. net product sales $161.4M in Q2 2026, up from $94.8M; FILSPARI sales $141.1M (+96% YoY).
- Net loss $34.8M ($0.37/share) vs $12.8M loss in Q2 2025; non-GAAP net loss $9.0M ($0.10/share).
- Cash $489.2M; issued $525M of 0.5% convertible notes due 2032, repurchased $221M of 2029 notes.
- In-licensed civorebrutinib from Everest Medicines for $112.5M upfront; plans to study in pMN, FSGS, MCD.
- Phase 3 HARMONY for pegtibatinase in HCU enrolling; topline data expected 2H 2027.

## SEC filing metadata
- accession: 0001438533-26-000062
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-08-04T20:05:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/0001438533-26-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/tvtx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000062
- JSON: https://secwatch.observer/filing/0001438533-26-000062.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.